[IPO 워치] 엔솔바이오, 이전상장 재도전 열쇠 '기술료 100억'

Ensol Biosciences' re-listing attempt hinges on realizing 1 billion won in technology royalties from two key drug candidates, P2K and E1K, marking a strategic shift from technology-centric to cash-flow-focused IPO positioning. The company's clinical progress on these peptide-based therapeutics and partnerships with SpineBioPharma and Readers Cosmetic provide near-term revenue catalysts essential for regulator approval.